chevron_leftBack
As of 24 April 2025, Onco-Innovations Ltd. has a market cap of $51.45M USD, ranking #24587 globally and #728 in Canada. It ranks #2492 in the Healthcare sector, and #797 in the Biotechnology industry.
Key Stats
Market Cap
$51.45MUSD
71.26M CAD
Enterprise Value
$51.05MUSD
70.84M CAD
Net Income (TTM)
-$46.48KUSD
-64.37K CAD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Thomas O’Shaughnessy
open_in_new
Employees
1
Website
oncoinnovations.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.1% | -11% | -26% | -22% | 137% | 137% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ONCO
Onco-Innovations Ltd
ISIN: CA68237C1059
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.42 CAD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Onco-Innovations Ltd.
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3′-phosphatase in a nanoparticle formulation based on the drug delivery technology. The company is headquartered in Calgary, Canada.
